SOLENO THERAPEUTICS INC — Income Charts
13 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$190M
Cost of Revenue
$3M
Gross Profit
$-59K
R&D↑+89.4% +$19M
$41M
SG&A
$132M
D&A↑+2.8% +$54K
$2M
Operating Income↑+129.9% +$41M
$9M
EBITDA↑+138.7% +$41M
$11M
Interest Expense
$5M
Interest Income
$17M
Other Income/Expense↓-100.0% -$618K
$0
Pretax Income↑+167.6% +$52M
$21M
Tax Provision
$0
Net Income↑+167.6% +$52M
$21M
Gross Margin
-4.0%
Operating Margin
4.9%
Net Margin
11.0%
Effective Tax Rate
0.0%
Deferred Tax Assets↑+55.7% +$29M
$80M
Deferred Tax Liabilities
$5M
DTA Valuation Allowance↑+55.7% +$29M
$80M
Tax Credit Carryforwards↑+526.8% +$17M
$21M
NOL Carryforwards↓-5.4% -$3M
$46M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-2.1%
ETR Foreign Differential (pp)
-0.6%
Operating Lease Cost↑+169.9% +$537K
$853K
Revenue YoY Variation
138.8%
Income YoY Variation↑+91.9pts
105.0%